ABMC Launches New Innovative Test System for the Rapid Detection of Drugs of Abuse in Oral Fluids
KINDERHOOK, N.Y.--(BUSINESS WIRE)--American Bio Medica Corporation (NASDAQ: ABMC) announced today that they have launched the patent pending OralStat® EX, a new oral fluid point of collection test that dramatically improves the limits of detection over other point of collection oral fluid drug tests on the market. The OralStat EX is simple to perform and the results are ready to read within minutes. The OralStat EX was developed for use in those markets where speed and accuracy are vital.
OralStat EX has been specifically designed to make both point of collection testing and confirmation testing simple. The OralStat EX collection swab has a volume indicator so that the correct volume is collected each time, ensuring optimal test performance. The oral fluid sample is then expressed into a separate transportable bottle containing a buffer solution, and after the initial screen has been performed there is ample solution remaining to send to a laboratory for confirmation of non- negative test results.
ABMC Chief Executive Officer Stan Cipkowski stated, “"The OralStat EX is the next generation of true oral fluid point of collection tests that do not require the use of any instrumentation. The development of the OralStat EX demonstrates ABMC’s continuing ability to enhance our current products to meet the ever-changing needs of our customers. We are confident that both current and perspective customers will enjoy the accuracy and ease of use benefits of using the OralStat EX.”
Oral fluid testing is becoming a more widely accepted alternative matrix for drugs of abuse detection. While the window of detection is more limited than traditional urine testing, oral fluid testing virtually eliminates issues associated with urine testing such as observed collection gender issues, dilution, adulteration, restroom availability, ease of specimen collection, and shy bladder.
For more information on ABMC or its drug testing products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid One®, Rapid TEC®, RDS® InCup® and Rapid TOX™ products test for the presence or absence of drugs of abuse in urine, while OralStat tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.